Enantiomer-dependent biodistribution and exposure determine the in vivo behavior of a pleurocidin-derived antimicrobial peptide
mBio · 2026
DOI: 10.1128/mbio.01718-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2026. Verfasst von Janis Romanopulos und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Antimicrobial Peptides, Fish Proteins, Anti-Bacterial Agents. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council, Medical Research Council, Schlumberger Faculty for the Future.
Abstract (Originalsprache)
Antimicrobial peptides (AMPs) display rapid bactericidal activity in vitro , but have largely failed as systemically administered therapeutics, indicating that intrinsic potency alone does not predict in vivo efficacy. Here, we examine how pharmacokinetics, stereochemistry, and host context shape early in vivo activity using pleurocidin-derived peptides. The D -amino-acid analog D-P-KR rapidly eradicates priority bacterial pathogens within minutes in vitro , achieving this at low multiples of the minimum inhibitory concentration (MIC) for Staphylococcus aureus but requiring higher multiples for Gram-negative species. Near-infrared imaging of fluorescently labeled enantiomers reveals that stereochemistry strongly influences systemic behavior, with D-enantiomers showing reduced renal and hepatobiliary clearance and increased exposure following intravenous administration. Despite these favorable properties, systemic D-P-KR does not reduce pulmonary bacterial burden within 2 h of treatment in mouse models of S. aureus or Klebsiella pneumoniae pneumonia. In contrast, increasing exposure through short intravenous infusion produces a rapid, exposure-dependent reduction in pulmonary neutrophil recruitment in S. aureus infection, without corresponding early changes in bacterial burden. This effect is not observed in the disseminating K. pneumoniae model. These findings demonstrate a dissociation between rapid in vitro killing, early bacterial clearance, and host-response modulation, and show that early in vivo AMP activity is governed primarily by systemic exposure and infection context. More broadly, this work highlights the need to integrate pharmacokinetics, dosing strategy, and host response when evaluating antimicrobial peptides for systemic use. IMPORTANCE Antimicrobial peptides can kill bacteria far more rapidly than most conventional antibiotics, yet very few have succeeded as systemically administered drugs. This study shows that differences in peptide stereochemistry profoundly influence how antimicrobial peptides distribute within the body and how long effective exposure can be maintained. Our findings demonstrate that strong antibacterial activity in vitro does not necessarily translate into early bacterial clearance in vivo , but that delivery strategies can still affect host responses during infection. By linking peptide stereochemistry, systemic exposure, and biological outcomes, this work highlights why many antimicrobial peptides struggle to translate clinically and underscores the need to prioritize pharmacokinetics, formulation, and dosing strategy alongside antibacterial potency during antimicrobial peptide development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.
- Antimicrobial Discovery, Development and Diagnostics (AD3), Countermeasures Development, Evaluation and Preparedness, UK Health Security Agency, London, United Kingdom.
- Centre for Biomolecular Spectroscopy and Randall Division of Cell and Molecular Biophysics, King's College London Randall Centre for Cell & Molecular Biophysics, London, United Kingdom.
ORCID-Profile: Janis Romanopulos, A James Mason
Förderung
- Biotechnology and Biological Sciences Research Council
- Medical Research Council
- Schlumberger Faculty for the Future
Zitieren
APA
Romanopulos, J., Cressey, P., Hind, C. K., Kim, S. H., Shalim, Z. A., Mohamed Akram, N., Alnasif Alhadi, H., Claxton, A., You, Y., Kelis, A. V., Ramsden, B., Memdouh, S., Jacob, A. C., Bui, T. T., Cleary, S. J., Thanou, M., Amison, R. T., Abbate, V., Sutton, J. M., & Mason, A. J. (2026). Enantiomer-dependent biodistribution and exposure determine the in vivo behavior of a pleurocidin-derived antimicrobial peptide. mBio. https://doi.org/10.1128/mbio.01718-26
Vancouver
Romanopulos J, Cressey P, Hind CK, Kim SH, Shalim ZA, Mohamed Akram N, et al. Enantiomer-dependent biodistribution and exposure determine the in vivo behavior of a pleurocidin-derived antimicrobial peptide. mBio. 2026. doi:10.1128/mbio.01718-26
BibTeX
@article{Romanopulos2026,
author = {Romanopulos, Janis and Cressey, Paul and Hind, Charlotte K and Kim, Seong-Heun and Shalim, Zayed A and Mohamed Akram, Nadiya and Alnasif Alhadi, Hala and Claxton, Amelia and You, Yuang and Kelis, Anna V and Ramsden, Bailey and Memdouh, Siham and Jacob, Ana C and Bui, Tam T and Cleary, Simon J and Thanou, Maya and Amison, Richard T and Abbate, Vincenzo and Sutton, J Mark and Mason, A James},
title = {Enantiomer-dependent biodistribution and exposure determine the in vivo behavior of a pleurocidin-derived antimicrobial peptide},
journal = {mBio},
year = {2026},
doi = {10.1128/mbio.01718-26}
}
EUVIMED